Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics

Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute...

Descripción completa

Detalles Bibliográficos
Autores principales: Andone, I, Anghelescu, A, Daia, C, Onose, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/
https://www.ncbi.nlm.nih.gov/pubmed/26351530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/
https://www.ncbi.nlm.nih.gov/pubmed/26351530

Ejemplares similares